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Abstract: There is a growing body of literature supporting the contribution of genetic variability 
to the mechanisms responsible for the adverse effects of antipsychotic medications particularly 
movement disorders and weight gain. Despite the current gap between research studies and the 
practical tools available to the clinician to identify such risks, it is hoped that in the foreseeable 
future, pharmacogenetics will become a critical aid to guide the development of personalized 
therapeutic regimes with fewer adverse effects. We provide a summary of two cases that are 
examples of using cytochrome P450 pharmacogenetics in an attempt to guide treatment in the 
context of recent literature concerning the role of pharmacogenetics in the manifestation of 
adverse effects of antipsychotic therapies. These examples and the review of recent literature 
on pharmacogenetics of antipsychotic adverse effects illustrate the potential for applying the 
principles of predictive, preventive, and personalized medicine to the therapy of psychotic 
disorders.
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Introduction
Antipsychotic drugs are widely prescribed for a multitude of psychiatric conditions. 
Approximately 36 million antipsychotic prescriptions were written in the United 
States in ambulatory care from 1997–2000 (Van Brunt et al 2003). In 2002 over one 
million prescriptions for antipsychotics were written for children and adolescents in 
ambulatory care (Olfson, Blanco et al 2006). There are signiﬁ  cant risks associated 
with ﬁ  rst and second-generation antipsychotics: weight gain, diabetes, hyperlipidemia 
particularly with the second-generation drugs (Haro et al 2006; Lambert et al 2006; 
Olfson, Marcus et al 2006), movement disorders (Joy et al 2006; Shirzadi et al 2006), 
hyperprolactinemia and cardiovascular adverse effects. It is unknown if these risks 
compound when antipsychotics are prescribed in combinations (Freundreich et al 
2002; Stahl et al 2004). Intolerable adverse effects and lack of efﬁ  cacy contribute to 
a signiﬁ  cant proportion of antipsychotic discontinuations (Lieberman 2005).
Pharmacogenetics explores the role of genetic factors in predicting drug response 
and potential side effects while pharmacogenomics explores the relationship between 
whole genome factors, drug response and potential side effects (Malhotra et al 2004; 
Lane et al 2005). The relatively new ﬁ  eld of pharmacogenetics studies pharmacokinetic 
and pharmacodynamic candidate genes.
Genes coding for proteins at which a drug acts are known as pharmacodynamic 
genes. Polymorphisms [genetic variations which occur with a frequency of 1% 
or more in population] of genes coding for dopamine and serotonin receptor and 
transporter proteins became obvious study candidates, based on the putative role of 
these neurotransmitters in the mechanism of action of ﬁ  rst and second generation 
antipsychotics (Malhotra et al 2004). The pharmacodynamic genes are difﬁ  cult to study 
partly because their measurable genetic effects (phenotypes) are clinical characteristics, 
which can be subject to the interaction between genes and environment.Neuropsychiatric Disease and Treatment 2007:3(6) 966
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The pharmacokinetic genes contribute to the differences 
in plasma level or tissue distribution of drugs. Examples of 
pharmacokinetic genes are those coding for cytochrome 
P450 (CYP450), a set of enzymes involved in the ﬁ  rst phase 
of metabolism of many antipsychotics. Some of CYP450 
genes are highly polymorphic and it is thought that their 
variations can contribute to side effects of antipsychotics. 
The function of these genes is known, and the phenotypes 
resulted from their polymorphisms can be characterized by 
measuring drug metabolic ratios (Dahl 2002). Numerous 
authors suggested that genotyping for families of CYP450 
enzymes (2D6, 2C19) could potentially aid in prescribing 
antipsychotic drugs (Dahl 2002; Kirchheiner 2004; de Leon, 
Armstrong et al 2006; Murray 2006). Cytochrome P450 
(CYP450) microsomal enzymes mediate approximately 
80% of the oxidative drug metabolism. More than 50% of 
the drugs responsible for adverse drug reactions are metabo-
lized by polymorphic phase-one metabolism enzymes and 
of these, 86% are CYP450 (Ingelman-Sundberg 2004). One 
or more CYP450 enzymes may contribute to the oxidative 
metabolism of a given drug (for example, aripiprazole is a 
substrate for CYP450 2D6 and 3A4 whereas risperidone is 
a major substrate for CYP450 2D6). CYP450 1A2 and 3A4 
are important in metabolism of antipsychotics (Dahl 2002; 
de Leon, Armstrong et al 2006) but individual genetic fac-
tors are yet to be clearly recognized in the activity of these 
enzymes (Ingelman-Sundberg 2004; Wilkinson 2005). 
CYP2D6 metabolizes many psychotropic drugs, including 
antipsychotics like haloperidol, thioridazine, perphenazine, 
chlorpromazine, risperidone, and aripiprazole as outlined 
in excellent reviews (Dahl 2002; Ingelman-Sundberg 2004; 
Murray 2006). CYP2D6 is a highly polymorphic gene with 
more than 70 variants, resulting in four phenotypes. Exten-
sive metabolizers (EMs) have one or two functional copies 
of the CYP2D6 gene and have normal metabolic rate of 2D6 
substrates. Intermediate metabolizers (IMs) have one non-
functional allele and one low activity 2D6 allele leading to 
lower than normal metabolic rate of substrates; in presence 
of a CYP2D6 inhibitor, the metabolic rate of substrates 
will be further reduced. Poor metabolizers (PMs) have two 
non-functional 2D6 alleles leading to no 2D6 activity and 
thus increased risk of adverse effects. Ultrarapid metabolizers 
(UMs) have three or more copies of a functional 2D6 gene; 
they metabolize substrates rapidly and may have limited 
clinical response at standard doses of drugs. Metabolizer cat-
egories have variable distribution between ethnic groups for 
example 5%–10% of Caucasians are poor metabolizers while 
29% of North Eastern Africans and Middle Easterners are 
ultrarapid metabolizers (Bradford 2002; Ingelman-Sundberg 
2004, de Leon, Armstrong et al 2006).
We will illustrate two clinical cases, which reﬂ  ect the 
burden of antipsychotic adverse effects and we will make an 
attempt to summarize aspects of pharmacogenetics related 
to antipsychotic tolerability.
Methods
Institutional review board approval was obtained to retro-
spectively review records on a group of patients genotyped 
for CYP450 with the FDA approved AmpliChip™ P450 test 
(Roche Diagnostics, Indianapolis, Indiana, USA) at Georgia 
Esoteric and Molecular Lab, as part of their routine clinical 
care in our clinic. We chose two cases to illustrate the burden 
of antipsychotic adverse effects.
Case A
Ms. A is a Caucasian female with bipolar I disorder. The 
patient was referred by neurology where she was seen for 
sedation, ataxia, vertigo, diplopia and headache, considered 
to be adverse effects from her psychotropic medication, 
lamotrigine at the time. The side effects ceased after lamotrig-
ine was discontinued. On initial evaluation she presented 
with irritable, labile, agitated mood, lack of sleep and racing 
thoughts. Medical and neurological studies including a com-
puterized tomography of the brain were unremarkable. In the 
past, patient has been treated with divalproex sodium, leading 
to weight gain, as well as carbamazepine and oxcarbazepine, 
which were ineffective. Risperidone caused her profound 
sedation and was discontinued quickly. Ms. A presented to 
the clinic on lithium 900 mg/day (at therapeutic level) and 
clonazepam 6 mg/day. Aripiprazole 5 mg daily was added 
for mood instability and was titrated up to 15 mg daily. On 
the subsequent visit Ms. A reported restlessness and urge 
to move constantly. Her symptoms of akathisia resolved 
after aripiprazole was discontinued. CYP450 genetic testing 
revealed CYP2D6 genotype *3/*5 with predicted phenotype 
of poor metabolizer and CYP2C19 genotype *1/*1 with 
predicted phenotype of extensive (normal) metabolizer. 
The patient eventually stabilized on lithium, clonazepam 
and topiramate.
Case B
Ms. B is a Caucasian female with schizophrenia. Ms. B 
initially presented on a combination of ziprasidone 120-mg 
daily, olanzapine 5 mg at bedtime, trazodone 100 mg at 
bedtime and benztropine 2 mg/day. Due to dizziness and 
sedation Ms. B was tapered off ziprasidone and olanzapine Neuropsychiatric Disease and Treatment 2007:3(6) 967
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and transitioned to quetiapine. Trazodone was discontinued. 
Over the next month, as the patient transitioned between 
antipsychotics and quetiapine was titrated to 400 mg daily she 
had excessive sweating, tachycardia and neck pain, gained 
approximately 20 pounds and had hallucinations. Benztro-
pine was continued for suspected residual extrapyramidal 
side effects from ziprasidone. Five months later, quetiapine 
was tapered and discontinued and ziprasidone reintroduced 
due to signiﬁ  cant weight gain on quetiapine. On ziprasidone 
100 mg daily, Ms. B lost 15 pounds but developed muscle 
stiffness, cogwheeling, tremor and night sweats. When 
benztropine was added she developed blurry vision. After 
ﬁ  ve more months, Ms. B was switched from ziprasidone 
to aripiprazole. Over the next 8 months Ms. B gradually 
began to experience sedation, gained ﬁ  fteen pounds, she 
developed difﬁ  culty with her gait, stiffness, cogwheeling and 
dyskinetic ocular movements. Her CYP450 genetic testing 
revealed CYP2D6 genotype *1/*41 with predicted phenotype 
extensive metabolizer and CYP2C19 genotype *1/*2 with 
predicted phenotype extensive metabolizer.
Discussion
The only FDA-approved pharmacogenetic test clinically 
available to our two patients was AmpliChip™ CYP450, 
which genotypes patients for CYP450 enzymes 2D6 and 
2C19. The AmpliChip P450, which was the ﬁ  rst microarray-
based test cleared by FDA, provides a highly comprehensive 
assessment of cytochrome P450 2D6 and 2C19 genotypes 
and detects the most common 20 CYP2D6 and 3 CYP2C19 
alleles. This test also differentiates the presence of multiple 
copies of functional or non-functional CYP2D6 gene, which 
is important to identify true ultrarapid metabolizers. Using 
this approach, patient A was found to have *3 and *5 for 
2D6 and allele *1 and *1 for 2C19 and patient B was found 
to have *1 and *41 for 2D6 and *1 and *2 for 2C19. This 
approach is effective in detecting inactive genotypes caused 
by mutations (ie, CYP2D6 *3 and CYP2C19*2) and gene 
deletion (ie, CYP2D6 *5) and genotypes associated with 
decreased activity of CYP2D6 enzyme (ie, CYP2D6 *41). 
The strength of this approach is the capability of the software 
to automatically express the complex genotypes in terms of 
four functional phenotypes for 2D6.
In case A, testing showed that the patient is a CYP 450 2D6 
poor metabolizer, which may explain her reactions to ris-
peridone and aripiprazole, since both of these antipsychotics 
are metabolized by CYP450 2D6. In case B, from the 
antipsychotics tried by the patient, the only major substrate 
for 2D6 was aripiprazole, although CYP450 2D6 has 
been implicated as a minor metabolic pathway for other 
antipsychotics including olanzapine and quetiapine (Dorado 
et al 2006). She is a CYP450 2D6 extensive (normal) 
metabolizer. In her case, CYP450 testing sheds no light on 
her remarkable history of sedation, weight gain and motor 
adverse effects from antipsychotics.
Association of genetic variations 
in CYP450 enzymes with antipsychotic 
treatment adverse effects
Did the patients’ test results inﬂ  uence our clinical decisions 
about their treatment with antipsychotics in the two cases 
described?
Risperidone is metabolized in the liver, through hydrox-
ylation to 9-hydroxyrisperidone by the CYP2D6 enzyme. 
The CYP2D6 PM phenotype was cited to correlate with 
risperidone side effects and discontinuation (de Leon, Susce 
et al 2005a). Risperidone steady state plasma concentration 
was shown to differ widely between 2D6 ultrarapid and poor 
metabolizers (Scordo et al 1999). Aripiprazole is metabolized 
by dehydrogenation, hydroxylation, and N-dealkylation. 
CYP3A4 and CYP2D6 enzymes are thought to be respon-
sible for dehydrogenation and hydroxylation of aripiprazole, 
while N-dealkylation is catalyzed by CYP3A4. There is little 
published information about the effect of CYP450 2D6 PM 
status on clinical effects of aripiprazole. In their review, 
Swainston-Harrison and Perry (2004) mention 60% higher 
exposure of CYP2D6 PM’s to total active moiety (aripipra-
zole and dehydro-aripiprazole) and almost double elimination 
half-life for PMs compared to EMs (146 vs 75 hours). No 
dosage adjustments are recommended for the 2D6 PMs in 
the manufacturer’s prescribing information but the document 
advises adjusting aripiprazole dose in presence of inhibitors 
and inducers of CYP450 2D6 [Bristol-Myers Squibb Com-
pany and Otsuka Pharmaceutical, Inc. AbilifyTM prescribing 
information, www.abilify.com accessed 2/16/07]. In a large 
naturalistic non-controlled study of two groups, patients 
treated with risperidone and patients who discontinued 
treatment with risperidone in a state hospital, the 2D6 PM 
phenotype appeared to increase the individual risk of adverse 
drug reactions from risperidone 2.5 times. However, across 
the entire population treated with risperidone in the same 
study, only 10%–20% of the adverse reactions were explained 
by the CYP450 2D6 PM status (de Leon, Susce et al 2006). 
Similarly, Brockmoller et al (2002), showed that that the 
risk of extrapyramidal side effects from haloperidol was 
signiﬁ  cantly higher in poor metabolizers of 2D6 but found 
that genotyping would prevent side effects in only 5% of Neuropsychiatric Disease and Treatment 2007:3(6) 968
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the people treated with haloperidol. There are limited but 
intriguing data showing that the cost of treating CYP2D6 
PM and UM patients is signiﬁ  cantly higher than that of 
treating patients with intermediate and extensive metabolizer 
phenotypes (Chou et al 2000). As it will be further shown 
in the section dedicated to tardive dyskinesia, CYP2D6 
polymorphisms have been primarily associated with move-
ment adverse effects from antipsychotics. In contrast with 
the limited guidance found in the medication prescription 
information, several sources offer dosing guidelines for 
antipsychotics with respect to use of concomitant competi-
tive substrates, inhibitors and inducers of CYP450 enzymes, 
as well as use in the case of patients with CYP450 genetic 
polymorphisms (Kirchheiner 2004; de Leon, Armstrong et al 
2005, 2006). Based on these published guidelines, in case 
A, if an antipsychotic is absolutely necessary, it would be 
reasonable to either prescribe antipsychotics not dependent 
of CYP450 2D6 such as clozapine, olanzapine, quetiapine 
or ziprasidone or use very low doses of 2D6-dependent 
antipsychotics. However, a clinician approaching case B has 
no available tools to guide him/her in the efforts to person-
alize this patient’s treatment, even in face of her extensive 
history of antipsychotic side effects.
A preponderance of pharmacogenetic studies of 
antipsychotics adverse effects addressed movement disorders 
(particularly tardive dyskinesia) and weight gain. Much 
less information is available about hyperprolactinemia, 
neuroleptic malignant syndrome and cardiovascular effects 
of antipsychotics.
Pharmacogenetic studies
of treatment-emergent movement 
disorders with antipsychotics
Extrapyramidal adverse effects of antipsychotics have been 
attributed to dopamine (D2) receptor blockade exceeding 80% 
(Kapur and Seeman 2001) and subsequently polymorphisms 
of genes coding for the dopamine D2 receptor family, which 
includes D2, D3 and D4 were studied extensively. Acute 
extrapyramidal effects including Parkinsonism, dystonia and 
akathisia have been the subject of very few pharmacogenetic 
studies: Mihara, Kondo et al (2001) and Kaiser et al (2002) 
found no association of D2 receptor polymorphisms with 
these side effects.
Akathisia, described by Barnes (1992) as a subjective 
feeling of restlessness, urge to move constantly and dyspho-
ria, is frequently present with ﬁ  rst generation antipsychotic 
agents, but 7%–8% patients experience it with second genera-
tion agents like risperidone and aripiprazole (Janssen L. P. 
Risperdal® prescribing information accessed 3/19/07 http://
www.risperdal.com/active/janus/en_US/assets/common/
company/pi/risperdal.pdf and Swainston-Harrison 2004). 
Akathisia has been regarded as a possible precursor of tardive 
dyskinesia (Eichhammer et al 2000) and its severity was 
related to tardive dyskinesia (TD) in the CATIE study (Miller, 
McEvoy et al 2005). Eichhammer et al (2000) reported that 
homozygotes for the Ser9Gly variant of dopamine DRD3 
gene polymorphism had signiﬁ  cantly higher incidence of 
akathisia than patients who were not homozygotes, after two 
weeks of treatment with haloperidol or equivalent.
TD is a hyperkinetic, purposeless, repetitive, persistent 
drug induced movement disorder which occurs in 
20%–30% of patients with prolonged antipsychotic treat-
ment (Chouinard 2004) and it has been a major focus 
of antipsychotic pharmacogenetic studies. CATIE study 
conﬁ  rmed that risk of tardive dyskinesia is associated to 
patient’s age, duration of antipsychotic exposure, exposure 
to conventional antipsychotics, anticholinergic medica-
tions, substance abuse, presence of extrapyramidal side 
effects and akathisia (Miller, McEvoy et al 2005). In addi-
tion to these known predictors, it is believed that a genetic 
component contributes to development of TD. Based on 
animal studies, pathophysiology of TD was attributed to 
up-regulation of the dopamine receptors and their hypersen-
sitivity due to dopamine blockade by antipsychotic drugs 
(Casey 2004). Here again, the dopamine D2-family of 
receptors have been the focus of pharmacogenetic studies, 
along with serotonin receptor polymorphisms and hepatic 
isoenzyme genes.
Although DRD2 has long been hypothesized to be the 
main target for antipsychotic medications, only a few of its 
polymorphisms have been investigated for their potential 
association with TD. Zai et al (2006) showed that from 
12 polymorphisms found on the DRD2 gene in a European 
Caucasian (n = 202) and African-American (n = 30) sample of 
patients with TD, only C957T and the adjacent C939T were 
signiﬁ  cantly associated with TD but not with its severity.
Steen (1997), Basile (1999), Segman (1999), Lerer 
(2002), de Leon, Susce et al (2005b) and others investigated 
the single nucleotide substitution which exists in the ﬁ  rst 
exon (coding sequence) of the D3 receptor gene, resulting in 
a serine to glycine (Ser9Gly) aminoacid change in the amino 
acid sequence of the receptor protein. All found indepen-
dently that the Ser9Gly DRD3 polymorphisms homozygous 
for glycine or containing the glycine allele are associated 
with increased the risk for TD. Other authors (Inada et al 
1997; Rietschel et al 2000 and Garcia-Barcelo et al 2001) did Neuropsychiatric Disease and Treatment 2007:3(6) 969
Pharmacogenetics of antipsychotic adverse effects
not ﬁ  nd association of DRD3 Ser9Gly polymorphism and 
TD. Interestingly, Jeanneteau et al (2006) demonstrated in a 
French sample that Ser9Gly variant of DRD3 was associated 
with risk and age at onset of essential tremor, a movement 
disorder unrelated to antipsychotic use. Although researchers 
recognized and attempted to control for variables like age, 
sex ethnicity and history of antipsychotic treatment it is likely 
that the contradictory ﬁ  ndings are related to these variables 
as well as the sample sizes and the differences in the study 
designs. Srivastava et al (2006) studied 24 polymorphisms on 
six dopaminergic genes, dopamine receptors DRD1, DRD2, 
DRD3, DRD4, DAT (dopamine transporter) and COMT 
(cathecol-O-methyltrasferase) in North Indian patients with 
schizophrenia. Only markers on DRD4 and COMT genes 
associated with TD in this patient population.
The association of serotonin receptor markers with TD 
was also explored. Segman et al (2001), Tan et al (2001), and 
Lerer et al (2005) found signiﬁ  cant associations of markers 
(genotypes and haplotypes) of the 5-HT2A receptor with 
TD but Basile et al (2001) did not replicate the ﬁ  ndings (a 
haplotype is a combination of alleles at closely linked gene 
loci on same chromosome (Malhotra et al 2004)).
In their review, Reynolds et al (2005) showed that sero-
tonin receptor 5HT2C polymorphisms were associated with 
TD in various ethnic populations treated with antipsychotics. 
Polymorphisms of metabolic enzymes like CYP450 genes 
CYP450 2D6, 1A2, 3A4, were studied to explore their poten-
tial association with TD. Kapitany et al (1998), Ohmori et al 
(1998), and Ellingrod et al (2000) found that polymorphisms 
of CYP450 2D6 resulting in reduced activity of this enzyme 
correlated positively with higher AIMS (Guy 1976) scores 
and the development of TD. Tiwari et al (2005) studied the 
association of CYP450 3A4 and 2D6 polymorphisms with 
TD in an Indian population. Despite of its highly variable 
expression, CYP450 3A4 functional polymorphisms are not 
clearly understood and 3A4*1B variant is no exception. Both 
CYP450 3A4*1B and 2D6*4 failed to show association with 
risk of TD. de Leon, Susce et al (2005b) studied the associa-
tion between tardive dyskinesia and genetic variations of 
pharmacokinetic genes, CYP2D6 or CYP3A5, pharmacody-
namic genes, DRD2 and DRD3, glutathione S-transferases 
(GSTT1 and GSTM1) which could be implicated in oxidative 
stress (and therefore possibly in TD mechanism) on white 
and African American mentally ill patients from Kentucky. 
Similar to the Indian sample (29%), 31% of people from 
the sample studied by de Leon had TD. In addition to the 
DRD2 results discussed above, gluthatione S-transferase M 
deﬁ  ciency associated with TD particularly in white women 
and there was a trend of association between 2D6 PM 
phenotype and TD.
Ellingrod and colleagues (2002) studied prospectively 
patients with schizophrenia genotyped for CYP2D6*1, 
*3, and *4 alleles, and collected data on their psychiatric 
symptoms, cigarette smoking status, and antipsychotic 
drug exposure. While no homozygotes were found for *3 
or *4 genotypes, the group of smokers with heterozygous 
CYP2D6 *3 or *4 genotype had the highest proportion of 
tardive dyskinesia (78%) compared with 2D6 *1/*1 smok-
ers or non-smokers (20%–33%). The authors concluded that 
patients with a low CYP2D6 activity due to presence of *3 
or *4 alleles may shunt antipsychotic metabolism through 
other pathways (for example CYP450 3A4) that are induced 
by cigarette smoking and that the induction may in turn result 
in formation of neurotoxic metabolites, possibly explaining 
higher frequency of tardive dyskinesia. Sachse et al (1997) 
found that the CYP2D6 polymorphisms did not predict TD 
but that the CYP1A2 polymorphisms were signiﬁ  cantly 
associated with TD. A polymorphism of CYP1A2 gene was 
signiﬁ  cantly associated with TD severity in a study by Basile 
et al (2000) with even more pronounced effect in the smoker 
group of the sample of Caucasians and African Americans, 
while Schulze et al (2001) did not replicate these results in 
a German sample.
Pharmacogenetic studies
of antipsychotic-related weight gain
Among the metabolic disturbances associated with the use 
of antipsychotic drugs, weight gain has come to the atten-
tion of patients, families, care providers and the general 
public especially with the development of second-generation 
antipsychotic drugs. Little is known about risk of obesity 
or diabetes in patients with schizophrenia independent of 
antipsychotic treatment (Regengold et al 2001; Ryan et al 
2003). In contrast, there is abundant information about the 
association of antipsychotic treatment with risk of obesity, 
cardiovascular disease and their dire consequences on 
general health and life expectancy (Hennekens et al 2006; 
Newcomer 2006; Sipos et al 2006). While risks of weight 
gain are deﬁ  ned for various antipsychotics (Müller and 
Kennedy 2006) front line practitioners have limited tools 
to predict why some patients develop obesity and diabetes 
and others do not when prescribed the same antipsychotic 
drugs. This individual variability can only lead one to sus-
pect that the interaction of genes and environment is heavily 
illustrated in this area. Müller and Kennedy (2006) list lower 
body mass index (BMI) at treatment onset as predictor of Neuropsychiatric Disease and Treatment 2007:3(6) 970
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weight gain for all antipsychotics, rapid and early weight 
gain with olanzapine as predictors of long term weight gain 
and similar BMI changes in monozygotic twins treated with 
same antipsychotic as available predictive tools.
Serotonin and leptin are two substances targeted by 
pharmacogenetic studies of antipsychotic induced weight 
gain. Serotonin’s role in feeding behavior was clariﬁ  ed by 
Tecott et al (1995) who showed that mice lacking functional 
serotonin 2C (5HT2c knockout mice) receptors were prone 
to increased feeding and weight gain. Leptin is a peptide 
secreted by fat cells in proportion to the body fat content and 
its higher serum levels decrease food intake and fat storage 
through action on hypothalamic nuclei (Muller and Kennedy 
2006). Second generation antipsychotics especially clozapine 
and olanzapine bind to the 5HT2C receptors and genetic 
variations of these receptors were studied in the attempt to 
understand the individual and racial differences in weight 
gain with antipsychotics.
In their review Reynolds et al (2005) summarize their 
own positive association studies between the 5HT2c –759C/T 
single nucleotide polymorphisms and weight gain in antipsy-
chotic naïve ﬁ  rst episode Chinese Han patients treated with 
chlorpromazine and risperidone and later with clozapine. 
Reynolds et al (2005) also cite other studies which found 
no association between the 5HT2c Cys23Ser polymorphism 
and weight gain from clozapine in Chinese and Caucasian 
and African Americans. Ellingrod et al (2005) and Miller, 
Ellingrod et al (2005) found that subjects with schizophrenia 
without the 5-HT2C-759T allele were at a higher risk of gain-
ing weight during treatment with olanzapine and respectively 
clozapine. Templeman et al (2005) studied polymorphisms 
of the both the serotonin 5-HT2C receptor and the leptin 
genes and their association with BMI and plasma leptin 
levels in Caucasian patients at 6 week, 3 and 9 months of 
treatment with various antipsychotic drugs. Consistent with 
other studies, they found subjects with 5-HT2C-759T allele 
had signiﬁ  cantly less weight gain than those without this 
allele. The leptin polymorphism studied (-2548A/G) was 
not associated with short-term weight gain but showed sig-
niﬁ  cant association with antipsychotic-induced weight gain 
at 9-months. The 5-HT2C-759 genotype was signiﬁ  cantly 
associated with pre-treatment plasma leptin levels. Ellingrod 
et al (2007) re-analyzed the patient sample from their previ-
ous study (Ellingrod et al 2005) for -2548G/A polymorphism 
of the leptin gene and Q223R A to G transition of the leptin 
receptor. They found a signiﬁ  cant relationship between 
alleles of the leptin and leptin receptor, olanzapine plasma 
concentrations and BMI. Subjects with at least one G allele 
at each locus had a threefold increase in BMI at olanzapine 
concentrations higher than 20.6 ng/ml. Authors postulated 
that a combination of impaired leptin expression and leptin 
receptor insensitivity may increase the risk of weight gain, 
especially in presence of antipsychotic drugs.
Pharmacogenetic studies of antipsychotic related hyperp-
rolactinemia are few, as reported by Reynolds et al (2006) in 
their review article. Mihara, Suzuki et al (2001) showed that 
a polymorphism of the dopamine D2 receptor gene Taq1 has 
been associated with greater prolactin response to bromperidol 
in female carriers of the A1 allele of this polymorphism on a 
Japanese sample of patients with schizophrenia and concluded 
that such patients may be at high risk for adverse effects asso-
ciated with neuroleptic-induced hyperprolactinemia. Young 
et al (2004) replicated this ﬁ  nding in a larger population of 
patients with various diagnoses stable for at least one month 
on various antipsychotic drugs. Their patients were divided in 
4 groups [clozapine, olanzapine, ﬁ  rst generation antipsychotics 
(FGA) and risperidone]. Patients in the FGA group with Taq1 
A1 allele had prolactin levels 40% higher and patients in the 
clozapine group had prolactin levels twice as high as those 
without the A1 allele.
Neuroleptic malignant syndrome (NMS) is a rare 
(0.02%–2%) complication of antipsychotic treatment but 
its mortality rate is 20%–30% (Wilkaitis 2004). Suzuki et al 
(2001) found an association between the Taq1 A1 allele and 
the risk of developing NMS in Japanese patients with schizo-
phrenia and replicated their own ﬁ  ndings in another study 
(Mihara et al 2003). In the latter study they also genotyped 
the subjects for the 141C Ins/Del D2 polymorphism and for 
the Ser(9)Gly polymorphism of dopamine D3 receptor, none 
of which were found to be associated with the risk of TD. Del 
Tacca et al (2005) reported a case in which a Caucasian patient 
diagnosed with NMS after taking risperidone and citalopram 
has been genotyped as heterozygous for dopamine D2 Taq1 
A1 allele. Kishida et al (2004) reported an association between 
141C Ins/Del D2 polymorphism and NMS but did not ﬁ  nd 
an association of the syndrome with D2 Taq1 A1 and the 
Ser(9)Gly polymorphism of dopamine D3 receptor.
Pharmacogenetics of antipsychotic 
cardiovascular side effects
QT interval prolongation is a warning sign for potentially 
life threatening Torsade de Pointes arrhythmia. Llerena 
et al (2004) studied a sample of white Europeans treated 
with risperidone and demonstrated that the QTc interval 
was longer in the subjects with one active CYP450 2D6 
gene compared with subject with two active genes. In their Neuropsychiatric Disease and Treatment 2007:3(6) 971
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review, Dorado et al (2006) describe that the number of CYP 
450 2D6 active genes was correlated with the QTc interval 
lengthening in patients treated with thioridazine and conclude 
that CYP450 2D6 phenotype and genotype must be taken 
into consideration in treatment with patients with other risk 
factors for long QT for example heart disease, congenital 
long QT, elderly.
There are signiﬁ  cant obstacles in face of clinical applica-
tions of pharmacogenetics. As frequently shown in our review, 
studies are difﬁ  cult to replicate likely because of sample size 
and ethnic variation of the genetic polymorphisms studied. 
The phenotypes studied to measure the effect of pharmacody-
namic genes are clinical characteristics. Such measurements 
can vary due to raters and due to intra-individual differences 
at various times in same patient. In addition, the interpreta-
tion of the association between identiﬁ  ed polymorphisms 
and the adverse effects is not always straightforward. Since 
they change the protein sequences, the interpretation of muta-
tions in the coding regions of pharmacodynamic genes is 
obvious. The mutations on the non-coding regions of a gene 
could potentially change the property of the gene product 
by regulating the transcription process, the splicing, and the 
stability of the mRNA. Further more, the polymorphism or 
mutation identiﬁ  ed in the non-coding region of a gene may 
not be responsible for the phenotype directly but may be 
linked to an unknown mutation located close to the studied 
polymorphism. The phenotype is the result of the interaction 
between genes and environment. In addition, the genes can 
have additive effect or even interact with each other. In this 
case, a certain polymorphism may have a functional effect 
on the phenotype in presence, but not in absence of another 
polymorphism (Lerer and Segman 2006).
Intermediate phenotypes measured with functional imag-
ing have been proposed (Blasi et al 2006) but they can be 
difﬁ  cult to apply in large patient samples and only add to the 
cost of already expensive pharmacogenetic testing.
Clinical applications of pharmacogenetic testing also 
faces considerable ethical and economic challenges. Most 
of the genetic polymorphisms described on our literature 
review are not available for testing outside academic research 
centers. However, some tests like AmpliChip P450 aimed 
at predicting CYP2D6 and 2C19 gene polymorphisms are 
cleared by FDA and are available commercially. However if 
such tests are not linked to a particular disease or a particular 
drug, their penetration in clinical practice may be difﬁ  cult 
(Williams-Jones et al 2007). Understandably, clinicians may 
be hesitant to apply pharmacogenetic testing as long as the 
regulation of various tests varies (Morley and Hall 2004), and 
there are no guidelines based on large sample sized studies to 
document their utility at the point of patient care (Ozdemir 
et al 2007). There is concern that certain individuals or popu-
lations who harbor disadvantageous polymorphisms may 
be discriminated against (Morley and Hall 2004). In the US 
the House of Representatives passed The Genetic Informa-
tion Nondiscrimination Act (HR 493) in 2007, which aims 
to prevent the use of genetic information to deny a person 
health insurance or job opportunities and makes it illegal for 
health insurance plans or to deny coverage to people based 
on a genetic predisposition to a disease. This bill is now 
considered in the US Senate.
Conclusions
Clinicians treating severe mental illness are eager to expand 
their understanding of the effects of antipsychotic treatment. 
We summarized here advances in pharmacogenetics, a ﬁ  eld 
that aims to help individualize treatment with antipsychotic 
drugs, to target optimal response and avoid risk of adverse 
effects. Drug response and tolerability are complex 
phenomena which involve additive and interactive effects of 
genes as well as multiple other factors like age, sex, ethnicity, 
concomitant disease, liver and kidney function, diet, smok-
ing, pregnancy and drug-drug interactions. It is thus under-
standable that the clinical applications of pharmacogenetics 
are developing and penetrating into practice slowly and most 
likely will compliment but not replace clinical monitoring 
of antipsychotics.
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